Radionuclide Therapies
At New York Imaging Specialists, we're revolutionizing cancer care through innovative, patient-centered approaches. Our cutting-edge treatments include radionuclide therapy, a precision form of targeted radiation that selectively destroys cancer cells while preserving healthy tissue. This advanced therapy offers new hope for patients with certain aggressive cancers.
What is Radionuclide Therapy?
Radionuclide therapy, also referred to as unsealed source radiotherapy or molecular radiotherapy, is a cutting-edge cancer treatment that harnesses the power of small amounts of radioactive materials to precision-target and destroy cancer cells. This innovative approach utilizes radiopharmaceutical drugs, which comprise a radioisotope ion bonded to a tailored organic molecule. Acting as a molecular guide, this molecule delivers the radioactive isotope directly to cancer cells, leveraging their unique antigens and receptors. Upon reaching the tumor, the radiopharmaceutical releases targeted radiation, damaging cancer cell DNA and inducing tumor shrinkage while minimizing harm to surrounding healthy tissue
How does Radionuclide Therapy Work?
Radionuclide therapy works by attaching radioactive isotopes to molecules that selectively bind to cancer cells. Once the radioactive molecules are absorbed by the cancer cells, they emit radiation that destroys the cells from the inside out, minimizing harm to surrounding healthy tissues.
What are the Types of Radionuclide Therapies?
There are several types of radionuclide therapies, including:
1. Alpha-particle therapy:
-
Uses alpha particles to destroy cancer cells.
2. Beta-particle therapy:
-
Uses beta particles to destroy cancer cells.
Meet the Game-Changers: Xofigo, Lutathera, and Pluvicto
Xofigo (Radium-223 Dichloride):
-
Approved for treating castration-resistant prostate cancer with symptomatic bone metastases.
-
Improves overall survival, delays skeletal events, and reduces pain.
Lutathera (Lutetium Lu 177 Dotatate):
-
Approved for treating advanced neuroendocrine tumors.
-
Improves progression-free survival, reduces tumor size, and enhances quality of life.
Pluvicto (Lutetium Lu 177 vipivotide tetraxetan):
-
Approved for treating PSMA-positive metastatic castration-resistant prostate cancer.
-
Improves progression-free survival, reduces tumor size, and enhances quality of life.
Who is a Candidate for Radionuclide Therapy?
Radionuclide therapy is most effective for patients with advanced or metastatic cancers who are no longer responding to conventional treatments or who have exhausted other treatment options. A doctor will determine eligibility based on:
-
Cancer type and stage
-
Failed or are intolerant to other treatments
-
Organ function and overall health
Empowering Hope, One Patient at a Time
Radionuclide therapies are revolutionizing cancer treatment, offering new hope and improved outcomes for patients. At NY Imaging, we're proud to be at the forefront of this innovation, delivering cutting-edge care with a patient-centered approach. Join us in the fight against cancer – contact New York Imaging Specialists today to learn more, call (833) 269-4624.